MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) is set to participate in Chardan’s 8th Annual Genetic Medicines Conference in New York City.
Dr. Arun Upadhyay, the company’s Chief Scientific Officer and Head of Research & Development, will take part in a fireside chat moderated by Daniil Gataulin, PhD. The event, occurring on September 30, 2024, will spotlight Ocugen’s pioneering work in gene therapy targeting retinal conditions like retinitis pigmentosa, geographic atrophy, and Stargardt disease.
“I am excited to speak about Ocugen’s groundbreaking modifier gene therapy approach in treating retinal diseases and on the progress of our ongoing clinical trials,” Dr. Upadhyay remarked.
This gathering allows Ocugen to engage with investors and share its mission. Additionally, Ocugen’s executive team will conduct one-on-one meetings to discuss the company’s strategic directions in business and clinical development.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.